/PRNewswire/ Dr. Eric Gulve has announced his retirement from BioSTL after 15 years as President of its startup arm, BioGenerator, and as Executive Vice.
Published: Jul 15, 2021 By Kate Goodwin
The NK program has taken off with multiple indications. According to Dan Kemp, its lead product, WU-NK-101, is already proving itself in an ongoing Phase I/II trial, demonstrating an impressive complete response rate in relapsed/refractory AML. It s the promising results of these memory NK cells driving
Company founder John McKearn
told BioSpace in January that Wugen started as a twinkle in his eye to bring a durable, allogeneic CAR-T therapy on the market. At that time, the biotech s natural killer (NK) cell program was a recent addition to its core focus on CAR-T therapy.
St Louis biotech startup Wugen raises $172M to advance its cancer-fighting therapies bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Arch Oncology Appoints Laurence Blumberg, M.D. President and CEO
April 07, 2021 08:00 ET | Source: Arch Oncology Arch Oncology Brisbane, California, UNITED STATES
BRISBANE, Calif. and ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the appointment of Laurence Blumberg, M.D. as President and Chief Executive Officer and Board Member. Dr. Blumberg has over thirty years of biotechnology industry experience leading companies as an executive, founder, analyst, and board member.
“On behalf of the Board, I welcome Laur to Arch Oncology as he brings extensive industry experience to lead the Company’s plans for AO-176, a novel anti-CD47 therapy for patients with cancer,” said John McKearn, Ph.D., Managing Director, RiverVest Venture Partners and Chairman of the Board of Arch Oncology.
Arch Oncology Appoints Laurence Blumberg, M.D. President and CEO
News Provided By
Share This Article
/EIN News/ BRISBANE, Calif. and ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the appointment of Laurence Blumberg, M.D. as President and Chief Executive Officer and Board Member. Dr. Blumberg has over thirty years of biotechnology industry experience leading companies as an executive, founder, analyst, and board member.
“On behalf of the Board, I welcome Laur to Arch Oncology as he brings extensive industry experience to lead the Company’s plans for AO-176, a novel anti-CD47 therapy for patients with cancer,” said John McKearn, Ph.D., Managing Director, RiverVest Venture Partners and Chairman of the Board of Arch Oncology. “AO-176 has a differentiated and potentially best-in-class profile among anti-CD47 biologic therap